Propylhexedrine Abuse Prompts US FDA To Suggest OTC Nasal Inhaler Modifications, Smaller Size

Researchers Say Little Attention Given To Decongestant Ingredient’s Abuse Risk

FDA published warning against abuse of propylhexedrine, but study published in October 2020 questioned why sales of products with the ingredient aren’t limited like sales of pseudoephedrine-containing OTCs under a federal law.

Another drug ingredient available OTC in the US could become a target for restricting sales by age as the Food and Drug Administration and public health researchers raise alarms about abuse of propylhexedrine, used in nasal decongestant inhalers.

While the FDA on 25 March published a warning against abuse of propylhexedrine, a study published in October 2020 questioned...